Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin

PHASE2CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

August 31, 2008

Conditions
Chronic Hepatitis C
Interventions
DRUG

NM283 plus Peg-IFNα-2a

200 mg QD 180 µg QW

Trial Locations (2)

Unknown

Atlanta

Fairfax

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY